JPWO2021048809A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021048809A5 JPWO2021048809A5 JP2022516358A JP2022516358A JPWO2021048809A5 JP WO2021048809 A5 JPWO2021048809 A5 JP WO2021048809A5 JP 2022516358 A JP2022516358 A JP 2022516358A JP 2022516358 A JP2022516358 A JP 2022516358A JP WO2021048809 A5 JPWO2021048809 A5 JP WO2021048809A5
- Authority
- JP
- Japan
- Prior art keywords
- hexahydro
- carbamoyl
- indacen
- cyano
- sulfonimidamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002554 vinyl polymer Polymers 0.000 claims 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 6
- 239000004202 carbamide Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- -1 ethene-1-sulfonimidamide hydrochloride Chemical compound 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 2
- GGPMIOXJGZGBID-JKDGHBIFSA-N C1=2CCCC=2C=C2C(=C1NC(=O)NS(=NC)(=O)/C=C/[C@@]1(CCCN1C)C)CCC2 Chemical compound C1=2CCCC=2C=C2C(=C1NC(=O)NS(=NC)(=O)/C=C/[C@@]1(CCCN1C)C)CCC2 GGPMIOXJGZGBID-JKDGHBIFSA-N 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 2
- 108090000171 Interleukin-18 Proteins 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 229940124291 BTK inhibitor Drugs 0.000 claims 1
- NRCUZRLFSOPNNX-SIEMXHSWSA-N C(#N)N=S(=O)(NC(NC1=C(C=C(C=C1C(C)C)F)C(C)C)=O)\C=C\[C@]1(N(CCC1)C(C)C)C Chemical class C(#N)N=S(=O)(NC(NC1=C(C=C(C=C1C(C)C)F)C(C)C)=O)\C=C\[C@]1(N(CCC1)C(C)C)C NRCUZRLFSOPNNX-SIEMXHSWSA-N 0.000 claims 1
- ZBVWUNJYSYNYFY-MEPFQPJUSA-N C(#N)N=S(=O)(NC(NC1=C(C=CC=C1C(C)C)C(C)C)=O)\C=C\[C@]1(N(CCC1)C(C)C)C Chemical compound C(#N)N=S(=O)(NC(NC1=C(C=CC=C1C(C)C)C(C)C)=O)\C=C\[C@]1(N(CCC1)C(C)C)C ZBVWUNJYSYNYFY-MEPFQPJUSA-N 0.000 claims 1
- QQFHXEGMRXMPAC-HIBSILBWSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@H]1N(CCC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@H]1N(CCC1)C QQFHXEGMRXMPAC-HIBSILBWSA-N 0.000 claims 1
- FZXSGXXANOASEV-CUZXEONSSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@H]1N(CCC1)S(=O)(=O)C1=C(C=CC=C1)C#N Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@H]1N(CCC1)S(=O)(=O)C1=C(C=CC=C1)C#N FZXSGXXANOASEV-CUZXEONSSA-N 0.000 claims 1
- YBYIEXSFCLQEOL-BDXMMPEESA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@H]1N(CCC1)S(=O)(=O)C1CCCCC1 Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@H]1N(CCC1)S(=O)(=O)C1CCCCC1 YBYIEXSFCLQEOL-BDXMMPEESA-N 0.000 claims 1
- WSAFPUMVXNBHLI-DDFORHRVSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@]1(N(CCC1)C)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@@]1(N(CCC1)C)C WSAFPUMVXNBHLI-DDFORHRVSA-N 0.000 claims 1
- UWRGVDISGJGXOF-ARUUENIKSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C(C)C)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C(C)C)C UWRGVDISGJGXOF-ARUUENIKSA-N 0.000 claims 1
- VJHIDVKCQQCOCN-PKIMYUMRSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCC1)C VJHIDVKCQQCOCN-PKIMYUMRSA-N 0.000 claims 1
- LYOCVLGMBISXRQ-LGYFCJLFSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCCC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCCC1)C LYOCVLGMBISXRQ-LGYFCJLFSA-N 0.000 claims 1
- MPWZOSDYTBMWEY-HDABHNHHSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCCCC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCCCC1)C MPWZOSDYTBMWEY-HDABHNHHSA-N 0.000 claims 1
- AFXQTXMGBMDYIK-ITTBXXDWSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCOCC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)C1CCOCC1)C AFXQTXMGBMDYIK-ITTBXXDWSA-N 0.000 claims 1
- MBJMLTOKZHTFCX-DJNPJXAGSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC(C)(N1CCCC1)C)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC(C)(N1CCCC1)C)C MBJMLTOKZHTFCX-DJNPJXAGSA-N 0.000 claims 1
- LNYMTYLWXBWRFG-YNRXLNIXSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC(C)C)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC(C)C)C LNYMTYLWXBWRFG-YNRXLNIXSA-N 0.000 claims 1
- BDEVFNNLWBWPRR-MMSQAAQDSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC)C BDEVFNNLWBWPRR-MMSQAAQDSA-N 0.000 claims 1
- HCRNZQYNHGFDEJ-YNRXLNIXSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC1CC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC1CC1)C HCRNZQYNHGFDEJ-YNRXLNIXSA-N 0.000 claims 1
- IVZWJRSHPBOJNR-NBHHVZBDSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC=1SC=CN=1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CC=1SC=CN=1)C IVZWJRSHPBOJNR-NBHHVZBDSA-N 0.000 claims 1
- QSWAIKWKBBTNSA-DPVHCVKFSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CCOC)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(N(CCC1)CCOC)C QSWAIKWKBBTNSA-DPVHCVKFSA-N 0.000 claims 1
- LIPWJXZJOJYVPV-RZABZGFVSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(NCCC1)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)\C=C\[C@]1(NCCC1)C LIPWJXZJOJYVPV-RZABZGFVSA-N 0.000 claims 1
- HIWGSJWYDMYXID-NTEXPWGHSA-N C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=C1C)=O)\C=C\[C@]1(N(CCC1)C(C)C)C Chemical compound C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=C1C)=O)\C=C\[C@]1(N(CCC1)C(C)C)C HIWGSJWYDMYXID-NTEXPWGHSA-N 0.000 claims 1
- FVFQJAZTWCRUFR-BRATWYHFSA-N C(#N)N=S(=O)(\C=C\[C@]1(N(CCC1)C(C)C)C)NC(CC1=C2CCCC2=CC=2CCCC1=2)=O Chemical compound C(#N)N=S(=O)(\C=C\[C@]1(N(CCC1)C(C)C)C)NC(CC1=C2CCCC2=CC=2CCCC1=2)=O FVFQJAZTWCRUFR-BRATWYHFSA-N 0.000 claims 1
- PQLGKWNAMSNCMF-HNRZKYARSA-M C(#N)N=S(=O)(\C=C\[C@]1(N(CCC1)C1CCCCC1)C)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[Na+] Chemical compound C(#N)N=S(=O)(\C=C\[C@]1(N(CCC1)C1CCCCC1)C)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[Na+] PQLGKWNAMSNCMF-HNRZKYARSA-M 0.000 claims 1
- QOGLALJTNRMARF-RHGJBDAQSA-M C(#N)N=S(=O)(\C=C\[C@]1(N(CCC1)CC(C)C)C)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[Na+] Chemical compound C(#N)N=S(=O)(\C=C\[C@]1(N(CCC1)CC(C)C)C)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[Na+] QOGLALJTNRMARF-RHGJBDAQSA-M 0.000 claims 1
- VYTZGEGMGNMKMJ-UHFFFAOYSA-N C(=C)S(=O)(=N)N Chemical compound C(=C)S(=O)(=N)N VYTZGEGMGNMKMJ-UHFFFAOYSA-N 0.000 claims 1
- YHQKJKJMHZBEPQ-GEXGBSOXSA-N C(C)(=O)N1[C@](CCC1)(C)/C=C/S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)=NC#N Chemical compound C(C)(=O)N1[C@](CCC1)(C)/C=C/S(=O)(NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)=NC#N YHQKJKJMHZBEPQ-GEXGBSOXSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- KAIGHJHEMHNGMK-BIUYHNAGSA-N CC1CCC2=C(C3=C(CCC3)N=C12)NC(=O)NS(=NC#N)(=O)/C=C/[C@@]4(CCCN4C)C Chemical compound CC1CCC2=C(C3=C(CCC3)N=C12)NC(=O)NS(=NC#N)(=O)/C=C/[C@@]4(CCCN4C)C KAIGHJHEMHNGMK-BIUYHNAGSA-N 0.000 claims 1
- KRBPGCJYQFGUMV-KASKBGTRSA-N C[C@@]1(CCCN1C)/C=C/S(=NC#N)(=O)NC(=O)CC2=C3CCCC3=CC4=C2CCC4 Chemical compound C[C@@]1(CCCN1C)/C=C/S(=NC#N)(=O)NC(=O)CC2=C3CCCC3=CC4=C2CCC4 KRBPGCJYQFGUMV-KASKBGTRSA-N 0.000 claims 1
- WSAFPUMVXNBHLI-KVFZBJKPSA-N C[C@]1(CCCN1C)/C=C/S(=NC#N)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4 Chemical compound C[C@]1(CCCN1C)/C=C/S(=NC#N)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4 WSAFPUMVXNBHLI-KVFZBJKPSA-N 0.000 claims 1
- AQZYMGZTRUJQLN-VSBZHSNNSA-N C[C@]1(CCCN1C)/C=C/S(=NC#N)(=O)NC(=O)NC2=C3CCCC3=NC4=C2CCC4 Chemical compound C[C@]1(CCCN1C)/C=C/S(=NC#N)(=O)NC(=O)NC2=C3CCCC3=NC4=C2CCC4 AQZYMGZTRUJQLN-VSBZHSNNSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- OQWHCSQRTBABCH-ODJCZEPSSA-N Cl.C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC12)=O)\C=C\[C@@]1(NCCC1)C Chemical compound Cl.C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC12)=O)\C=C\[C@@]1(NCCC1)C OQWHCSQRTBABCH-ODJCZEPSSA-N 0.000 claims 1
- OQWHCSQRTBABCH-IJLAUSNMSA-N Cl.C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC12)=O)\C=C\[C@]1(NCCC1)C Chemical compound Cl.C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC12)=O)\C=C\[C@]1(NCCC1)C OQWHCSQRTBABCH-IJLAUSNMSA-N 0.000 claims 1
- BIHVTRZINBDKEW-IJLAUSNMSA-N FC(C(=O)O)(F)F.C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC12)=O)\C=C\[C@]1(NCCC1)C Chemical compound FC(C(=O)O)(F)F.C(#N)N=S(=O)(NC(NC1=C2CCCC2=CC=2CCCC12)=O)\C=C\[C@]1(NCCC1)C BIHVTRZINBDKEW-IJLAUSNMSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921036803 | 2019-09-12 | ||
| IN201921036803 | 2019-09-12 | ||
| PCT/IB2020/058464 WO2021048809A1 (en) | 2019-09-12 | 2020-09-11 | Novel substituted sulfoximine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548869A JP2022548869A (ja) | 2022-11-22 |
| JP2022548869A5 JP2022548869A5 (https=) | 2023-08-01 |
| JPWO2021048809A5 true JPWO2021048809A5 (https=) | 2023-08-01 |
Family
ID=74866664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516358A Pending JP2022548869A (ja) | 2019-09-12 | 2020-09-11 | 新規な置換スルホキシミン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12377070B2 (https=) |
| EP (1) | EP4027986A4 (https=) |
| JP (1) | JP2022548869A (https=) |
| CN (1) | CN114746087A (https=) |
| WO (1) | WO2021048809A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024180521A1 (en) * | 2023-03-02 | 2024-09-06 | Zydus Lifesciences Limited | Treatment for inflammatory bowel disease |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666506A (en) * | 1984-08-08 | 1987-05-19 | E. I. Du Pont De Nemours And Company | Herbicidal pyrimidines |
| US5258406A (en) | 1991-12-20 | 1993-11-02 | Eli Lilly And Company | Sulfonimidamides |
| PT1270565E (pt) * | 1997-01-29 | 2004-09-30 | Pfizer | Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| SI3259253T1 (sl) | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| EP3668840A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) * | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| EP3692020A1 (en) * | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| EA202191968A1 (ru) * | 2019-01-14 | 2021-11-16 | Кадила Хелзкэр Лимитед | Новые замещенные производные сульфонилмочевины |
| EP4110058A4 (en) * | 2020-02-28 | 2024-03-20 | Zydus Lifesciences Limited | Novel substituted sulfonylurea and sulfoximineurea derivatives |
-
2020
- 2020-09-11 US US17/642,184 patent/US12377070B2/en active Active
- 2020-09-11 CN CN202080078065.1A patent/CN114746087A/zh active Pending
- 2020-09-11 EP EP20862312.4A patent/EP4027986A4/en active Pending
- 2020-09-11 JP JP2022516358A patent/JP2022548869A/ja active Pending
- 2020-09-11 WO PCT/IB2020/058464 patent/WO2021048809A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516395A5 (https=) | ||
| JP2021011495A5 (https=) | ||
| RU2454411C2 (ru) | Производные хинолина | |
| US20040209930A1 (en) | Synergistic methods and compositions for treating cancer | |
| JP2014511869A5 (https=) | ||
| RU2004117545A (ru) | Аминопиримидины и пиридины | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| HRP20140737T1 (hr) | Inhibitori hepatitis c virusa | |
| RU2221796C2 (ru) | Производные аминов | |
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| RU2007119315A (ru) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний | |
| JP2010540452A5 (https=) | ||
| JP2011504497A5 (https=) | ||
| RU2001130452A (ru) | Циклические ингибиторы протеинтирозинкиназ | |
| RU2005109561A (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| RU2001129155A (ru) | Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале | |
| RU2009112598A (ru) | Модуляторы киназы, ассоциированной с рецептором интерлейкина-1 | |
| RU95112537A (ru) | Терапевтические гетероциклические соединения, способ их получения, фармацевтическая композиция, способ ее получения | |
| JP2010533158A5 (https=) | ||
| RU2001127082A (ru) | Производные аминов | |
| HRP20220297T1 (hr) | Aminoimidazopiridazini kao inhibitori kinaze | |
| JP2013533317A5 (https=) | ||
| RU2003118448A (ru) | Производные замещенного триазолдиамина и их применение в качестве ингибиторов киназы | |
| JP2005511608A5 (https=) | ||
| RU2005107463A (ru) | Циклические протеины ингибиторов тирозинкиназы |